Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

Today, frequent discussion occurs surrounding the issue of non-medical exemptions for vaccination requirements for children ...

A new Crohn’s treatment that involves guselkumab showed outstandingly greater rates of endoscopic improvement, which are vital for reducing long-term complications.

Proponents of reining in the largely unregulated intoxicating hemp industry in Texas shared new polling data on Wednesday ...

Guselkumab, a medication with a mechanism of action that is new to inflammatory bowel disease (IBD) treatment, outperformed ...

Intravenous induction followed by subcutaneous maintenance therapy with guselkumab is efficacious for adults with moderately ...

Gut support cells communicate with surprising precision – like brain neurons – using tiny extensions to send instructions to ...

In this video, Joseph M. Runde, DO, attending physician in gastroenterology, hepatology and nutrition at Ann & Robert H. Lurie Children’s Hospital of Chicago and assistant professor of pediatrics at ...

Changes in sleep metrics detected with wearable technology could serve as an inflammation marker and potentially predict IBD ...

Vitamin E and selenium are essential antioxidants that support immune function and protect against cell damage. Learn about ...

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.